Christine Landlinger
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Targeting of oxidized Macrophage Migration Inhibitory Factor (oxMIF) with antibody ON104 attenuates the severity of glomerulonephritis.
Journal: PloS one
Published: May 24, 2024
The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis.
Journal: European journal of pharmacology
Published: May 08, 2023
Preclinical Data on the Gardnerella-Specific Endolysin PM-477 Indicate Its Potential to Improve the Treatment of Bacterial Vaginosis through Enhanced Biofilm Removal and Avoidance of Resistance.
Journal: Antimicrobial agents and chemotherapy
Published: April 13, 2022
Optimization of Propidium Monoazide qPCR (Viability-qPCR) to Quantify the Killing by the Gardnerella-Specific Endolysin PM-477, Directly in Vaginal Samples from Women with Bacterial Vaginosis.
Journal: Antibiotics (Basel, Switzerland)
Published: December 17, 2021
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
Journal: European journal of clinical pharmacology
Published: March 09, 2021
Engineered Phage Endolysin Eliminates Gardnerella Biofilm without Damaging Beneficial Bacteria in Bacterial Vaginosis Ex Vivo.
Journal: Pathogens (Basel, Switzerland)
Published: December 08, 2020
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.
Journal: European heart journal
Published: October 18, 2016
Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer's disease.
Journal: Journal of neuroinflammation
Published: April 30, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026